CytomX Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	34.19	38.05	17.17	193.65	205.53	191.86
Short-Term Investments	109.44	62.57	157.34	-	99.7	124.26
Cash & Short-Term Investments	143.63	100.62	174.51	193.65	305.23	316.12
Cash Growth	22.14%	-42.34%	-9.88%	-36.55%	-3.45%	6.74%
Receivables	1.63	3.1	3.43	35.99	0.79	0.8
Prepaid Expenses	3.96	3.58	5	7.47	4.29	7.1
Total Current Assets	149.22	107.31	182.94	237.1	310.3	324.01
Property, Plant & Equipment	6.54	10.6	16.18	21.02	25.32	29.45
Goodwill	0.95	0.95	0.95	0.95	0.95	0.95
Other Intangible Assets	0.47	0.58	0.73	0.88	1.02	1.17
Other Long-Term Assets	1.08	1.09	1	0.94	1.82	3.09
Total Assets	158.25	120.53	201.79	260.89	339.41	358.66
Accounts Payable	0.65	1.09	1.46	2.81	2.82	3
Accrued Expenses	12.32	12.34	17.6	22.82	30.62	19.86
Current Portion of Leases	5.6	5.15	4.59	4.08	3.62	3.2
Current Unearned Revenue	22.38	67.2	132.27	121.27	40.82	42.06
Other Current Liabilities	0.09	-	-	1.63	-	-
Total Current Liabilities	41.03	85.77	155.91	152.61	77.87	68.11
Long-Term Leases	-	4.24	9.39	13.98	18.06	21.68
Long-Term Unearned Revenue	5.54	26.86	80.05	180.06	243.94	276.65
Other Long-Term Liabilities	4.3	4.12	3.89	-	-	-
Total Liabilities	50.87	120.99	249.24	346.64	339.87	366.44
Common Stock	0	0	0	0	0	0
Additional Paid-In Capital	789.72	691.1	675.91	637.12	623.34	499.96
Retained Earnings	-682.44	-691.58	-723.45	-722.88	-623.56	-507.69
Comprehensive Income & Other	0.1	0.03	0.1	0.01	-0.24	-0.05
Total Common Equity	107.39	-0.46	-47.45	-85.75	-0.46	-7.77
Shareholders' Equity	107.39	-0.46	-47.45	-85.75	-0.46	-7.77
Total Liabilities & Equity	158.25	120.53	201.79	260.89	339.41	358.66
Total Debt	5.6	9.39	13.97	18.06	21.67	24.87
Net Cash (Debt)	138.03	91.24	160.54	175.59	283.55	291.25
Net Cash Growth	29.01%	-43.17%	-8.58%	-38.07%	-2.64%	8.49%
Net Cash Per Share	1.17	1.08	2.18	2.67	4.42	6.31
Filing Date Shares Outstanding	169.44	80.1	67.72	66.23	65.39	64.78
Total Common Shares Outstanding	165.07	80.1	67.31	66.23	65.39	48.25
Working Capital	108.19	21.53	27.02	84.49	232.43	255.9
Book Value Per Share	0.65	-0.01	-0.70	-1.29	-0.01	-0.16
Tangible Book Value	105.97	-1.99	-49.13	-87.58	-2.43	-9.89
Tangible Book Value Per Share	0.64	-0.02	-0.73	-1.32	-0.04	-0.20
Machinery	-	16.69	16.3	17	17.75	16.4
Construction In Progress	-	-	0.37	0.71	0.31	0.25
Leasehold Improvements	-	2.01	1.98	1.74	1.74	1.73

Source: S&P Global Market Intelligence. Standard template. Financial Sources.